A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Clinical trial NCT07059845 · RECRUITING
Trial details
- NCT number
- NCT07059845
- Sponsor
- AbbVie
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-13
- Primary completion
- 2029-01-01
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.